Replaces Prod. #: ALX-850-280
The Osteoprotegerin (human) ELISA kit is a complete, colorimetric, immunometric immunoassay kit for the quantitative determination of osteoprotegerin in plasma and serum with results in just ~5 hours.
Product Details
| Alternative Name: | OPG, TNFRSF 11B, Tumor Necrosis Factor receptor superfamily member 11B, Osteoclastogenesis Inhibitory Factor, OCIF |
| |
| Sensitivity: | 1.4pg/ml (range 0 to 500pg/ml) |
| |
| Assay Time: | ~5 hours |
| |
| Applications: | ELISA, Colorimetric detection
|
| |
| Application Notes: | For the quantitative determination of human osteoprotegerin in serum and plasma. |
| |
| Wavelength: | 450 nm |
| |
| Species reactivity: | Human
|
| |
| Quantity: | 96 wells (~80 tests). |
| |
| Shipping: | Blue Ice Not Frozen |
| |
| Long Term Storage: | +4°C |
| |
| Contents: | Plate pre-coated with capture antibody, Wash buffer, Detection antibody, Standards, Control, Assay buffer, Conjugate Streptavidin-HRP, TMB solution, Stop solution |
| |
| Scientific Background: | Osteoprotegerin (OPG) or osteoclast inhibitory factor (OCIF) is a glycoprotein of the TNF receptor superfamily 11b (gene name TNFRSF11B). OPG is synthesized as a monomer of 380 amino acids and is assembled as a homodimer within the cell, and then secreted mainly as a disulfide-linked homodimer into the extracellular compartment. OPG is produced by many different tissues and cell types including osteoblasts. OPG is a negative regulator of bone resorption by acting as decoy receptor for RANKL, thus neutralizing its function in osteoclastogenesis. This glycoprotein is also involved in the regulation of vascular calcification. |
| |
| UniProt ID: | O00300 |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
| Compatibility: | This product is compatible with the Absorbance 96 Plate Reader.
 |
| |
Product Literature References
Activation of the p53 pathway down-regulates the osteoprotegerin (OPG) expression and release by vascular endothelial cells: P. Secchiero, et al.; Blood
111, 1287 (2008),
Abstract;
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo: G. Zauli, et al.; Blood
110, 536 (2007),
Abstract;
An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction: P. Secchiero, et al.; Am. J. Pathol.
169, 2236 (2006),
Abstract;
Full Text
Related Products
